Verve Therapeutics, Inc. - VERV STOCK NEWS

Verve Therapeutics announces participation in the Guggenheim 2023 Genomic Medicines and Rare Disease Day on April 3, 2023. CEO Sekar Kathiresan will engage in a fireside chat at 10:45 a.m. ET, providing insights into the company's innovative approaches to cardiovascular disease treatment through gene editing.

The event will be available via a live webcast on the company’s website, archived for 30 days. Verve focuses on VERVE-101 and VERVE-201, targeting genes to lower LDL cholesterol, addressing conditions like familial hypercholesterolemia and atherosclerotic cardiovascular disease.

Verve Therapeutics announced promising preclinical data for its gene editing candidate, VERVE-201, aimed at treating homozygous familial hypercholesterolemia (HoFH). The data, presented at the 2023 American College of Cardiology's Annual Scientific Sessions, demonstrated significant, durable editing of the ANGPTL3 gene in non-human primates, achieving up to 96% reduction of ANGPTL3 protein levels and up to 54% reduction in triglycerides. Verve plans to initiate a clinical trial in 2024, targeting patients with HoFH. This single-course gene editing approach may transform cardiovascular disease management, reducing the treatment burden of existing therapies.

Verve Therapeutics reported updates on its clinical pipeline and financial results for Q4 and full-year 2022. The heart-1 clinical trial of VERVE-101 is ongoing in New Zealand and the UK, with initial data expected in H2 2023. The company holds $554.8 million in cash, enough to fund operations into mid-2025. Collaboration revenue reached $1.0 million in Q4 2022, while R&D expenses increased to $37.3 million. The net loss was $41.1 million for the quarter. Positive regulatory advancements include the recent Innovation Passport award for VERVE-101 by the UK MHRA, aiming to accelerate patient access.

Verve Therapeutics has announced that its investigational gene editing medicine, VERVE-101, has received the Innovation Passport designation from the UK’s MHRA for treating heterozygous familial hypercholesterolemia (HeFH). This designation aims to expedite the development and patient access to innovative treatments. VERVE-101 is designed to permanently turn off the PCSK9 gene in the liver, potentially lowering LDL cholesterol levels significantly. The ongoing Heart-1 clinical trial, assessing VERVE-101’s safety and efficacy, is expected to produce initial data in late 2023, which marks a critical step for the company and its mission to transform cardiovascular care.

Verve Therapeutics, a clinical-stage biotechnology firm, will have its CEO, Sekar Kathiresan, present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023, at 4:30 p.m. PT in San Francisco. The live presentation will be accessible via webcast, archived for 30 days. Verve focuses on innovative gene editing therapies for cardiovascular disease, notably through programs VERVE-101 and VERVE-201, aimed at lowering LDL cholesterol levels to combat heart disease.

Verve Therapeutics, a clinical-stage biotechnology firm, focuses on innovative gene editing therapies for cardiovascular diseases. CEO Sekar Kathiresan will present at two investor conferences: the Jefferies London Healthcare Conference on November 15, 2022, and the Evercore ISI Virtual HealthCONx Conference on November 29, 2022. These events will be broadcast live and archived for 60 days. Notably, their programs VERVE-101 and VERVE-201 aim to lower LDL cholesterol levels by targeting specific genes, potentially transforming chronic care into a single treatment solution.

Verve Therapeutics announced that the FDA has placed a hold on its IND application for VERVE-101, an investigational gene editing treatment for heterozygous familial hypercholesterolemia (HeFH). Despite this, dosing has been completed in the first cohort of the heart-1 clinical trial in New Zealand and the U.K., with no adverse events reported. The company is well-capitalized with $550.7 million in cash, enough to fund operations into the second half of 2025. R&D expenses rose to $35.2 million, contributing to a net loss of $45.2 million for Q3 2022.

Verve Therapeutics recently received the Paul Dudley White International Scholar Award from the American Heart Association for the highest-ranked abstract from the U.S. at Scientific Sessions 2022. This recognition is based on preclinical results for VERVE-101, a gene editing medicine targeting PCSK9 to lower LDL cholesterol in patients with heterozygous familial hypercholesterolemia (HeFH). The study in non-human primates showed significant reductions in both PCSK9 protein and LDL cholesterol levels, with no germline transmission. The data will be presented at the AHA meeting from November 5-7, 2022.

Verve Therapeutics, a biotechnology company focused on cardiovascular disease, has announced its participation in several investor conferences. Key events include the Guggenheim 2022 Nantucket Therapeutics Conference on September 28, the Jefferies Cell and Genetic Medicine Summit on September 29, the Chardan 6th Annual Genetic Medicine Conference on October 4, the BMO Virtual Biopharma Spotlight Series on October 6, and the Truist Securities Genetic Medicine Summit on October 20.

Live webcasts will be available on the company’s investor website for 60 days post-event.